Quoin Pharmaceuticals Reports Positive Interim Phase 2/3 Data for QRX003 in Netherton Syndrome
Ashburn, Va. – August 28, 2026 Quoin Pharmaceuticals announced positive interim results from the ongoing Phase 2/3 CL-QRX003-004 study...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Ashburn, Va. – August 28, 2026 Quoin Pharmaceuticals announced positive interim results from the ongoing Phase 2/3 CL-QRX003-004 study...
Basel, Switzerland – August 28, 2026 Roche announced new two-year results from the Phase IIIb/IV SALWEEN study evaluating Vabysmo®...
